Avicena is proud to announce the acceptance of its patent for the High-Throughput Screening Apparatus (Avicena Sentinel) in Japan and Saudi Arabia, marking another major step in the protection and commercialisation of Avicena’s breakthrough biosecurity technologies.
The Sentinel platform represents a new class of high-throughput diagnostic systems, combining automation, multiplexing, and precision detection to enable rapid, scalable screening across human health, animal health, and national outbreak preparedness.
These new patents strengthen Avicena’s global intellectual property portfolio and support the company’s ongoing expansion into key international markets with partners committed to transforming health.
Avicena continues to advance a pipeline of next-generation technologies with the potential to redefine how the world detects, prevents, and responds to infectious disease threats.